Masahiro Takeuchi

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara et al. · The Lancet Oncology · 2008 · 1.9K citations

Surgical Oncology, Spirits Trial, Gastrointestinal Oncology +8

TRAF6 is a signal transducer for interleukin-1

Zhaodan Cao, Jessie Xiong, Masahiro Takeuchi et al. · Nature · 1996 · 1.3K citations

Inflammation, Cytokine, Signal Transduction +7

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

Hajime Uno, Brian Claggett, Lü Tian et al. · Journal of Clinical Oncology · 2014 · 721 citations · Full text

Retrospective Cohort Study, Between-group Difference, Cancer Epidemiology +15

YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts

Takahito Nakahara, Masahiro Takeuchi, Isao Kinoyama et al. · Cancer Research · 2007 · 502 citations

Urology, Induces Regression, Chemoprevention Strategy +14

The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex

Hong-Bing Shu, Masahiro Takeuchi, David V. Goeddel · Proceedings of the National Academy of Sciences · 1996 · 420 citations